pharma news today glp-1 obesity drugs today What is the pipeline for future medications for obesity? WHO GLP-1 Treatments: WHO Endorses
Description
Mark Clements Lost over 170 lbs *Personal results may vary based on our individualized health programs
[DOI] [PubMed] [Google Scholar] 471.Ahren B., Lindskog S., van Dijk G., Scheurink A.J., Steffens A.B
The safety profile of the new drugs also still needs to be improved, as does patient access to the new therapies
63 Both GLP-1RA and SGLT2-I offer minimal risk of hypoglycemia and appear to have positive, although modest, effects on weight and BP
The results were promising as the primary composite outcome (first occurrence of three-point MACE) occurred in 608 out of the 4668 patients (13.0%) treated with liraglutide as compared to 694 out of the 4672 patients (14.9%) in the placebo group
The complex of spore-forming probiotics supports and improves gut barrier health
